U.S. Markets close in 1 hr 45 mins

Amicus Therapeutics, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / November 8, 2017 / Amicus Therapeutics, Inc. (NASDAQ: FOLD) will be discussing their earnings results in their Q3 Earnings Call to be held on November 8, 2017 at 8:30 AM Eastern Time.

To listen to the event live or access a replay of the call - visit https://www.investornetwork.com/company/24147.

To receive updates for this company you can register by emailing info@investornetwork.com or by clicking get investment info from the company's profile.

About Investor Network

Investor Network (IN) is a financial content community, serving millions of unique investors market information, earnings, commentary and news on the what's trending. Dedicated to both the professional and the average traders, IN offers timely, trusted and relevant financial information for virtually every investor. IN is an Issuer Direct brand, to learn more or for the latest financial news and market information, visit www.investornetwork.com. Follow us on Twitter @investornetwork.

SOURCE: Investor Network

  • Companies Say They're Ready to Move Supply Chains From China
    Finance
    Bloomberg

    Companies Say They're Ready to Move Supply Chains From China

    U.S. President Donald Trump imposed a 10 percent tariff on $200 billion of Chinese imports in September -- following an earlier round of tariffs on $50 billion of goods -- and promised to raise the duty to 25 percent in January. "We’re pro-actively taking action," Todd Bluedorn, chief executive officer of the Texas-based HVAC company, told analysts during an Oct. 22 earnings call. "We have various levers to pull to mitigate the impact," Frans van Houten, CEO of the Dutch healthcare and lighting technology company, said during an Oct. 22 earnings call.

  • Business
    Benzinga

    Morgan Stanley: 6 Ways Caesars Entertainment Can Create Value

    Gaming operator Caesars Entertainment Corporation (NASDAQ: CZR) boasts multiple upside catalysts that imply the stock is undervalued, according to Morgan Stanley. The Analyst Morgan Stanley's Thomas Allen initiated coverage of Caesars Entertainment 

  • 2 More Marijuana Stocks Are Moving to the NYSE
    Business
    Motley Fool

    2 More Marijuana Stocks Are Moving to the NYSE

    This year, we've witnessed GW Pharmaceuticals gain approval in the U.S. for the first cannabis-derived drug, and we watched as Vermont legalized recreational marijuana use entirely through the legislative process. This began with Cronos Group at the end of February, when it chose to list its shares on the Nasdaq. It was followed just a few months later by Canopy Growth Corp., which became the first marijuana stock to list on the NYSE.

  • Why Tesla Stock Jumped Tuesday
    Business
    Motley Fool

    Why Tesla Stock Jumped Tuesday

    Shares of electric-car company Tesla (NASDAQ: TSLA) popped on Tuesday, rising as much as 7.5%. The stock's rise comes after the electric-car company scheduled its earnings report about a week earlier than usual with just two days' notice, leading to some speculation that the automaker may have achieved its goal to become profitable during the quarter. Citron Research, which had previously encouraged investors to short Tesla stock, is now reversing its stance on the stock.

  • Why Investors Are Paying a Premium for These 3 Biotech Stocks
    Business
    Motley Fool

    Why Investors Are Paying a Premium for These 3 Biotech Stocks

    Amarin stock exploded in September because it looks like Vascepa will become the next go-to drug for this enormous population. During the 8,179-patient Reduce-It trial, patients given Vascepa in addition to their normal statin treatments were 25% less likely to suffer a major cardiovascular event such as a heart attack. Over the past year, Amarin Corporation actually lost $92 million because sales of Vascepa just haven't kept pace with operating expenses.

  • Larry Kudlow details plans for Trump's middle-income tax cut
    Business
    Fox Business Videos

    Larry Kudlow details plans for Trump's middle-income tax cut

    President Trump commits to a new middle-income tax reduction of 10 percent to be voted on after Election Day; Director of the National Economic Council Larry Kudlow explains.

  • Suze Orman missed the point of retirement, and that’s why she went back to work
    News
    MarketWatch

    Suze Orman missed the point of retirement, and that’s why she went back to work

    Suze Orman did a smackdown of the FIRE (Financial Independence/Retire Early) movement on Paula Pant’s podcast. Coach Carson posted a balanced, informative response, appreciating Suze’s admonition to be sure you have enough for a risk-free retirement. Suze enumerated a string “what can go wrong” scenarios as evidence that early retirement (on less than $10 million) leaves you vulnerable when life hands you lemons — a whole tree of lemons.

  • 5 Deeply Discounted Value Stocks That Haven't Been This Cheap in at Least a Decade
    Business
    Motley Fool

    5 Deeply Discounted Value Stocks That Haven't Been This Cheap in at Least a Decade

    October has been a wake-up call for investors that the stock market won't go up in a straight line, even if we'd like it to. Sure, Bank of America (NYSE: BAC) has seen its stock catapult higher from its Great Recession lows, but its forward P/E of 9.8 would represent a more-than-decade low for the stock.

  • Finance
    CNBC

    Here's the tax bite on $1.6 billion Mega Millions and $620 million Powerball jackpots

    Strategies can be employed to reduce the amount of your win that is taxed, although they are best explored with the help of an experienced tax advisor. While it's anyone's guess who will end up winning the Mega Millions and Powerball jackpots, there's at least one guaranteed recipient of a chunk of the loot — the IRS. With the Mega Millions jackpot at $1.6 billion and Powerball's top prize at $620 million, that tax bill will be hefty even if the winner employs strategies to reduce their taxable income.

  • T-Mobile CEO said he'd rather live in Kansas City than Bellevue
    Finance
    American City Business Journals

    T-Mobile CEO said he'd rather live in Kansas City than Bellevue

    T-Mobile US Inc. CEO John Legere said he would rather live in Kansas City than Bellevue, and T-Mobile plans to make new “centers of employment” with or without a Sprint Corp. merger. The details emerged after Legere spoke at an employee meeting at Sprint headquarters. Sprint was required to provide a transcript to the U.S. Securities and Exchange Commission because it discussed the company’s planned $26.5 billion merger bid with T-Mobile.

  • Is the New Energy Transfer LP a Buy?
    Finance
    Motley Fool

    Is the New Energy Transfer LP a Buy?

    Last week, Energy Transfer LP (NYSE: ET) emerged on the scene after the former Energy Transfer Equity completed the acquisition of its affiliate Energy Transfer Partners in a unit-for-unit exchange that simplified this complex midstream franchise. The transaction also created a much stronger company that has the financial resources to fund a significant slate of expansion projects. The new Energy Transfer is a behemoth in the midstream sector.

  • Business
    Motley Fool

    Parsing Visa's Big Quarterly Dividend Hike

    The ubiquitous financial services player Visa (NYSE: V) isn't exactly an income stock -- its dividend yield has fairly consistently been below 1% for years. Which raises two interesting questions for MarketFoolery host Chris Hill and senior analyst Jason Moser. In this segment from MarketFoolery, they discuss Visa's cash cow structure, its stock repurchases, and the M&A possibilities it thus far seems to be ignoring.

  • Business
    Barrons.com

    Micron Technology Is Under the Gun as Demand Outlook Worsens

    The price of (MU) stock has fallen nearly 40% since the summer, but the upside has diminished as well, according to Susquehanna analyst Mehdi Hosseini. “Recent checks imply incremental weakness in Cloud and Enterprise spending expectations” for the first half of 2019, Hosseini wrote on Tuesday. Hosseini lowered his price target for Micron to $45 from $75, implying upside of about 17% from the current level.

  • These stocks may be sacrificed in a cold war with China
    COL
    CNBC Videos

    These stocks may be sacrificed in a cold war with China

    Jim Cramer says the escalation in the United States' trade war with China could end in an outright cold war that debilitates parts of the stock market.

  • News
    CNBC

    Here's how much money you should have saved by 50

    Fidelity, the nation's largest retirement-plan provider, recommends having the equivalent of six times your annual salary saved. To get to that number, Fidelity recommends saving 15 percent of your annual income. Make sure to invest these funds instead of leaving them in a traditional low-interest savings account.

  • The stock market's 'dead cat bounce' is over and the rolling bear market is making a comeback, Morgan Stanley says
    Business
    Business Insider

    The stock market's 'dead cat bounce' is over and the rolling bear market is making a comeback, Morgan Stanley says

    The stock market may have bounced back from its sharp sell-off at the beginning of October, but Morgan Stanley says the selling will pick back up soon. The firm expects the S&P 500 to slide back below the 200-day moving average, a key technical level. Tread carefully in tech and consumer discretionary, Morgan Stanley warns.

  • Why These 3 Top Marijuana Stocks Slumped Today
    Business
    Motley Fool

    Why These 3 Top Marijuana Stocks Slumped Today

    With earnings season hitting a crescendo this week, investors are looking closely at the specific prospects for certain corners of the market, and that's contributing to disparities among the various major benchmarks followed most often by investors. Amid the crosscurrents, marijuana stocks took particularly hard hits, and New Age Beverages (NASDAQ: NBEV), Tilray (NASDAQ: TLRY), and Canopy Growth (NYSE: CGC) were among the worst performers on the day. All three of these stocks have given back some of their gains following the long-awaited legalization of recreational cannabis in the Canadian market last week. In the month leading up to the Oct. 17 start date for legal cannabis sales, New Age Beverages tripled in value, while Tilray had more than doubled since the end of August, and Canopy Growth had seen more modest gains of between 10% and 20%.

  • Dow tumbles nearly 550 points at lows amid corporate outlook, China selloff
    News
    MarketWatch

    Dow tumbles nearly 550 points at lows amid corporate outlook, China selloff

    It was a punishing start for stocks Tuesday as investors reacted negatively to quarterly results from a handful of blue chips and the cessation of a two-day rebound for China’s embattled stock market, reviving fresh questions about global economic growth prospects. The Dow Jones Industrial Average (DJIA) 548.62 points at its low and remained was recently 460 points, or 1.8%, at 24,862. The S&P 500 (SPX) fell 55 points, or 2%, to 2,696, retreating below a psychological and technical mark at 2,700, while the Nasdaq Composite Index (COMP) slid gave up 177 points, or 2.4%, to 7,291.

  • Business
    Barrons.com

    Microsoft Looks Set to Beat Earnings Expectations Again

    If history is any indication, analysts are understandably bullish about Microsoft’s first-quarter earnings on Wednesday—especially in the wake of its drubbing during tech’s big selloff earlier this month. (MSFT) (MSFT) has beaten analysts’ revenue estimates 19 of the last 20 quarters, and it is expected to report earnings of 96 cents per share on revenue of $27.88 billion, each up 14% from a year ago, according to FactSet. More important, Microsoft’s earnings should provide a key harbinger for the state of tech.

  • Why Nektar Therapeutics Crashed 17.2% Today
    Business
    Motley Fool

    Why Nektar Therapeutics Crashed 17.2% Today

    After delivering a disappointing update on NKTR-214 in cancer patients this summer, Nektar Therapeutics' (NASDAQ: NKTR) shares have been struggling. The company didn't report any news today, so a negative report issued by Plainview LLC this month may be to blamed for its 17.2% tumble today. In February, Bristol-Myers Squibb (NYSE: BMY) inked a blockbuster deal to license rights to NKTR-214 following positive data last year for NKTR-214's use alongside Bristol-Myers' Opdivo.

  • What the Market Missed in Kinder Morgan Inc.'s Results
    Business
    Motley Fool

    What the Market Missed in Kinder Morgan Inc.'s Results

    Kinder Morgan (NYSE: KMI) can't seem to catch a break these days. Despite its completing what management dubbed a "momentous" quarter, shares of the natural gas pipeline giant barely budged this week. It was a head-scratching outcome considering that its financial results came in well above its guidance, which the market seems to have completely missed.

  • Verizon beats Wall Street estimates, shares hit 18-year high
    Business
    Reuters

    Verizon beats Wall Street estimates, shares hit 18-year high

    The largest U.S. wireless carrier by subscribers has been focusing on upgrading its network and winning over more customers in a saturated market as rivals AT&T Inc , Sprint Corp and T-Mobile have been focusing on merger deals and paying down debt. Verizon shares rose 3.4 percent to $56.87, their highest in more than 18 years. The company said it added a net 295,000 phone subscribers who pay a monthly bill during the third quarter, easily beating the estimate of 161,000 provided by research firm FactSet.

  • Stocks plunge, Dow drops more than 300 points
    Finance
    Yahoo Finance

    Stocks plunge, Dow drops more than 300 points

    US equities took a nosedive Tuesday, extending a rout in global stocks. The Dow (^DJI) slid 1.31%, or 332.69 points, as of 1:01 p.m. ET, as major manufacturers Caterpillar and 3M posted disappointing financial results. The S&P 500 (^GSPC) fell 1.32%,

  • What to Expect from Bristol-Myers Squibb’s Q3 Earnings
    Finance
    Market Realist

    What to Expect from Bristol-Myers Squibb’s Q3 Earnings

    Bristol-Myers Squibb (BMY) is expected to report its third-quarter earnings on October 25. Analysts expect Bristol-Myers Squibb’s revenues to increase 8.87% from $5.25 billion in the third quarter of 2017 to $5.72 billion in the third quarte of 2018. In the last four quarters, Bristol-Myers Squibb’s revenue growth has been 3.93%–10.89%.

  • Weed stocks are tanking as Aurora Cannabis debuts on the New York Stock Exchange (TLRY, CRON, CGC)
    Business
    Business Insider

    Weed stocks are tanking as Aurora Cannabis debuts on the New York Stock Exchange (TLRY, CRON, CGC)

    Aurora Cannabis made its trading debut on the New York Stock Exchange. Weed stocks are getting slammed across the board, trading down between 7% and 14% before paring their losses. Weed stocks were under pressure Tuesday morning as one of the largest cannabis producers, Aurora Cannabis, debuted for trading on the New York Stock Exchange.